Company Overview
AEON Biopharma, Inc. operates as a clinical stage biopharmaceutical company dedicated to the development of botulinum toxins for the treatment of debilitating medical conditions, specifically focusing on the creation of ABP-450 (prabotulinumtoxinA) injection therapies. The firm functions within the healthcare sector and the biotechnology industry, environments characterized by rigorous research requirements and significant capital expenditure for product development. As of the latest available data, the company maintains a market capitalization of $29.35 million while reporting N/A for annual revenue and employing a workforce of 5 individuals. The combination of a sub-$30 million market cap, lack of reported revenue, and a minimal employee base indicates that AEON is a pre-revenue entity in an early stage of commercial viability, relying entirely on future clinical success to transition toward profitability.
Financial Health
The company reports N/A for revenue over the trailing twelve months, a net income of $-3,000, and an EBITDA of $-16,786,000, revealing a financial structure where operational expenses vastly exceed any generated income. The disparity between the nominal net income of $-3,000 and the substantial EBITDA loss of $-16.786 million highlights a cost structure dominated by non-operating expenses or significant adjustments not reflected in the primary operating EBITDA line item. Free cash flow stands at $-7,082,875, indicating that the company is consuming cash reserves rapidly to fund its clinical trials and operational overhead, thereby limiting its immediate financial flexibility for strategic acquisitions or expansion. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, which suggests that the company has not yet achieved positive gross profitability or sustained operating leverage necessary to generate a profit margin. On the liability side, the company holds $5.93 million in cash against $18.25 million in debt, while the debt-to-equity ratio is listed as N/A, pointing to a balance sheet that is heavily leveraged relative to its minimal equity base. The current ratio of 0.90 further underscores liquidity constraints, as current liabilities exceed current assets, signaling potential difficulty in meeting short-term obligations without additional financing or asset sales. Return on Equity is N/A due to the lack of positive equity returns, while Return on Assets sits at -165.5%, revealing that the company's assets are currently generating significant losses rather than returns.
Valuation Assessment
The trailing twelve-month P/E ratio is 0.39, whereas the forward P/E is -1.68, a divergence that implies the market expects earnings to remain negative in the near future rather than anticipate immediate profitability. The price-to-book ratio is -0.68, indicating that the market values the company at a negative multiple of its book value, a common characteristic for biotechnology firms with significant intangible assets or liabilities that are not fully captured on the balance sheet. Alternative valuation metrics such as the price-to-sales ratio, which is N/A due to zero revenue, and the EV/EBITDA of -1.55, suggest that traditional valuation multiples are not applicable, forcing reliance on clinical pipeline milestones rather than current financial performance. The stock trades between a 52-week high of $1.45 and a 52-week low of $0.38, meaning the current valuation is positioned within this historical range but is heavily dependent on future catalysts to move toward the upper bound. With a beta of 0.71, the stock exhibits lower volatility relative to the broader market, suggesting that price movements are less sensitive to general market swings compared to high-beta equities.
Growth & Income
Revenue growth and earnings growth rates are both listed as N/A, reflecting the absence of historical revenue data required to calculate year-over-year percentage changes. Because the company has not generated positive revenue, earnings are not growing faster than revenue in a traditional sense, as the primary focus remains on advancing clinical programs rather than scaling commercial sales. As a non-dividend payer, the company does not distribute a dividend yield or maintain a payout ratio, meaning the $-3,000 net income is retained entirely to fund ongoing research and development activities. The overall growth and income profile is defined by a lack of current financial generation, with all resources directed toward the development of ABP-450 and the completion of Phase 2 studies for cervical dystonia and other indications.